January 19, 2024
Atezolizumab, a programmed death-ligand 1 (PD-L1) inhibitor, has shown promising results in clinical trials when combined with chemotherapy for the treatment of extensive-stage small cell lung cancer (ES-SCLC). However, a real-world evaluation of atezolizumab plus platinum-etoposide chemotherapy in patients with ES-SCLC in Canada raises important considerations regarding its use.
